Clinical trials are exploring inhibitors of CTLA-4 and TGF-β for pancreatic cancer, with early-phase studies indicating that combining these inhibitors with immune checkpoint blockade can enhance anti-tumor immune responses and improve outcomes (41). Here, TGFB1 is linked to familial pancreatic carcinoma.